Accelrys Materials Studio Enhances Modeling and Simulation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Accelrys Materials Studio Enhances Modeling and Simulation

Equipment and Processing Report

Accelrys Materials Studio 7.0 modeling and simulation environment contains enhancements in quantum mechanics, classical simulation, usability, visualization, and collaboration to enable scientists to engineer better performing and more cost-effective materials. The software enables scientists to perform highly complex materials research using multi-scale simulation methods to construct, manipulate, and view models of molecules, crystalline materials, surfaces, polymers, and mesoscale structures. An improved solubility-property prediction provides better understanding of solvation properties. By understanding and predicting the relationships between a material's atomic and molecular structure and its properties and behaviors, materials scientists can develop better performing materials of all types faster and more efficiently than with test and experimentation alone.

Source: Accelrys


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Equipment and Processing Report,
Click here